

Publikationen 2001

Originalpublikationen in wissenschaftlichen Zeitschriften

1. Battegay M, Vernazza P, Bernasconi E, Flepp M, Sendi P, Erb P, Malinverni R, Jaccard C, Morgenthaler S., Bedoucha V, Hirschel B, for the Swiss HIV Cohort Study. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naïve patients. *HIV Medicine* 2001;2:35-42.
2. Bernasconi E, Jost J, Ledergerber B, Hirschel B, Francioli P, Sudre P. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997–2000. *Swiss Med Wkly* 2001;131:433-437.
3. Bisset LR, Cone RW, Fischer M, Battegay M, Vernazza PL, Weber R, Dubs RW, Grob PJ, Opravil M, and the Swiss HIV Cohort Study. Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. *J Acquir Immune Defic Syndr* 2001;27:266-271.
4. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave J-P, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A, for the Swiss HIV Cohort Study. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study. *Clin Infect Dis* 2001;33:1931–7.
5. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, Goldsmith MA. Folate receptor-a is a cofactor for cellular entry by Marburg and Ebola Viruses. *Cell* 2001;106, 117-126.
6. Eich-Höchli D, Niklowitz M, Eich P, Zellweger U, Opravil M. Gibt es Prädiktoren für sexuelles Risikoverhalten bei HIV-Infizierten? [Predictors of sexual risk behavior in HIV-infected persons.] *Nervenarzt* 2001;72:216-223.
7. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M and Telenti A for the Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: The Swiss HIV Cohort Study. *Lancet* 2001;358:1322-27.
8. Fleisch F, Zbinden R, Vanoli C, Ruef C. Epidemic Spread of a Single Clone of Methicillin-Resistant *Staphylococcus aureus* among Injection Drug Users in Zurich, Switzerland. *Clinical Infect Dis*: 2001;32: 581-586.
9. Friedl A, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E and Weber R, for the Swiss HIV Cohort Study. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. *AIDS* 2001;15:1793-1800.
10. Frost SDW, Günthard HF, Wong JK, Havlir D, Richman DD and Leigh Brown AJ. Evidence for positive selection driving the evolution of HIV envelope under potent antiviral therapy. *Virology* 2001;284:250-258.

11. Funk GA, Fischer M, Joos B, Opravil M, Günthard HF, Ledergerber B, Bonhoeffer S. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. *J Acquir Immune Defic Syndr* 2001;26:397–404.
12. Furrer H, Opravil M, Rossi M, Bernasconi E, Telenti A, Bucher H, Schiffer V, Boggian K, Rickenbach M, Flepp M, Egger M, and the Swiss HIV Cohort Study. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of *Pneumocystis pneumonia*: Prospective multicentre study. *AIDS* 2001;15:501-507.
13. Furrer HJ, Chan P, Weber R, Egger M for the Swiss HIV Cohort Study. Increased risk of wasting syndrome in HIV-infected travellers: Prospective multicentre study. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 2001;95:484-486.
14. Günthard HF, Havlir DV, Fiscus S, Zhang Z, Eron J, Mellors J, Gulick R, Frost SDW, Leigh Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, Wong JK. Residual Human Immunodeficiency Virus (HIV) Type 1 RNA and DNA in Lymph Nodes and HIV RNA in Genital Secretions and in Cerebrospinal Fluid after Suppression of Viremia for 2 Years. *Journal of Infectious Diseases* 2001;183:1318-1327.
15. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of Influenza Vaccination on Viral Replication and Immune Response in HIV Infected Persons Receiving Potent Antiretroviral Therapy. *Journal of Infectious Diseases* 2000;181:522-531.
16. Hauser PM, Blanc DS, Sudre P, Senggen Manoloff E, Nahiman A, Bille J, Weber R, Francioli P. Genetic diversity of *Pneumocystis carinii* in HIV-positive and - negative patients as revealed by PCR-SSCP typing. *AIDS* 2001;15:461-466.
17. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK. Prevalence and Predictive Value of Intermittent Viremia in HIV-1 Infected Patients Treated with Indinavir, Zidovudine, and Lamivudine. *JAMA* 2001;286:171-179.
18. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S; the CNA3002 European Study Team. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. *HIV Med* 2001;2:27-34.
19. Keppler OT, Yonemoto W, Welte FJ, Patton Sklacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA. Susceptibility of Rat-Derived Cells to Replication by Human Immunodeficiency Virus Type 1. *J Virol.* 2001;75: 8063-73.
20. Kronenberg A, Riehle HM, Günthard HF. Liver failure after long-term nucleoside antiretroviral therapy. (Letter) *Lancet* 2001;358:759-760.

21. Kronenberg A, Seebach JD, Bossart W, Weber R. Polyclonal expansion of large granular lymphocytes during cytomegalovirus primoinfection in a chronically HIV-infected patient on antiretroviral therapy. *Clin Infect Dis* 2001; 33:E34-36.
22. Kronenberg A, Seebach JD, Bossart W, Weber R. Polyclonal proliferation of large granular lymphocytes during cytomegalovirus primary infection in a human immunodeficiency virus-infected patient receiving antiretroviral therapy. *Clin Infect Dis* 2001;33:E34-6.
23. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, d'Arminio Monforte A, Schneider MME and Lundgren JD for eight European study groups. Discontinuation of secondary prophylaxis against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus infection who have a response to antiretroviral therapy. *N England J M* 2001;344:168-174.
24. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren JD on behalf of the EuroSIDA study group. The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. *AIDS* 2001;15:201-209.
25. Oxenius A, Günthard HF, Hirschel B, Fidler S, Weber JN, Easterbrook PJ, Bell JI, Phillips RE, Price DA. Direct ex vivo analysis reveals distinct phenotypic patterns of HIV epitope-specific CD8+ T lymphocyte activation in response to therapeutic manipulation of virus load. *Eur J Immunology* 2001;31:1115-1121.
26. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD on behalf of the EuroSIDA study group. HIV viral load outcome of non-nucleoside reverse transcriptase inhibitor-containing regimens for 2203 mainly antiretroviral-experienced patients. *AIDS* 2001;15:2385-2395.
27. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B on behalf of the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort and the EuroSIDA Study Group. Initiation of antiretroviral therapy: HIV-1 viral load response according to the baseline CD4 lymphocyte count and viral load. *JAMA* 2001;286:2560-2567.
28. Proudfoot, AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C, Trkola A, Marchant D, Clapham PR, Wells TN. The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity. *J Biol Chem* 2001;276:10620-10626.
29. Roos F, Flepp M, Figueras G, Bodmer T, Furrer H and the Swiss HIV Cohort Study. Clinical manifestations and predictors of survival in AIDS patients with disseminated *Mycobacterium avium* infection. *Eur J Clin Microbiol Infect Dis* 2001;20:428-442.
30. Rossi M, Flepp M, Telenti A, Schiffer V, Egloff N, Bucher H, Vernazza P, Bernasconi E, Weber R, Rickenbach M, Furrer H, and the Swiss HIV Cohort Study. Disseminated *M.avium* infection in the Swiss HIV Cohort Study:

Declining incidence, improved prognosis and interruption of maintenance therapy. *Swiss Med Wkly* 2001;131:471-478.

31. Sax H, Friedl A, Renner E, Steuerwald MH, Weber R, for the Swiss HIV Cohort Study. Pilot study of interferon- α with and without amantadine for the treatment of hepatitis C in HIV co-infected individuals on antiretroviral therapy. *Infection* 2001;29:267-270.
32. Schüpbach J, Böni J, Flepp M, Tomasik Z, Joller H, Opravil M. Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA. *J Med Virol* 2001;65:225-232
33. Sokolovic E, Schmidlin D, Schmid ER, Turina M, Ruef C, Schwenkglenks M, Szucs T. (2001) Determinants of costs and resource utilisation associated with open heart surgery. *European Heart Journal* 0: 1-5 (elektronisch publiziert, Dez. 2001)
34. Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. *Swiss Med Wkly* 2001; 131:663–665
35. Spenlehauer, C, Gordon CA, Trkola A, and Moore JP. A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1. *Virology* 2001; 280:292-300.
36. Strizki JM, Xu S, Wagner N, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Sherry Shapiro, Clader JW, Tagat J, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, MooreJP, Reyes GR, Baroudy BM. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. *Proc Natl Acad Sci USA*. 2001;98:12718-23.
37. Szucs T, Ruef C, Müller D, Sokolovic E, Beeler I, Ostermayer W. The economic impact of influenza in a university hospital setting. *Infect Control Hosp Epidemiol* 2001;22: 472-474
38. The Delta Coordinating Committee [Aber V, Aboulker J-P, Babiker AG, Bragman K, Breckenridge AM, Carbon C, Charreau I, Chene G, Collis P, Cooper D, Darbyshire J.H, Dormont J, Fiddian P, Flepp M, Gazzard B, Goebel FD, Hooker M, Lange J, Mosconi G, Lüthy R, Peto TEA, Reiss P, Seligmann M, Stone AB, Thomis J, Vella S, Walckenaer G, Warrell D, Weller IVD, Wilber R, Yeni P, Yeo J, Withnall R.] Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up. *HIV Medicine* 2001;2:181-188.
39. The Initio Coordinating Committee [Cooper D, Yeni P, Angarano G, Antunes F, Churchill D, Conway B, Flepp M, Lelekis M, Gatell J, Girard PM, Hemmer R, Lundgren J, Mijch A, Mulcahy F, Ristola M, Salzberger B, Sandström E, Staszewski S, Weber J, De Wit S.] An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1

Infection: Design, Rationale, and Methods of the Initio Trial. *Controlled Clinical Trials* 2001;22:160-175.

40. Weber R, Bossart W, Cone R, Lüthy R, Moelling K. Phase I Clinical Trial with HIV-1 gp160 Plasmid Vaccine in HIV-1-infected Asymptomatic Subjects. *Eur J Clin Microbiol Infect Dis* 2001;20:800-803.
41. Yerly S., Vora S, Rizzardì P, Chave J-P, Vernazza P, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L, and the Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. *AIDS* 2001;15:2287-2292
42. Zinkernagel C, Taffé P, Rickenbach M, Amiet R, Ledergerber B, Volkart AC, Rauchfleisch U, Kiss A, Werder V, Vernazza P, and Battegay M. Importance of mental health assessment in HIV infected outpatients. *J Acquir Immune Defic Syndr* 2001;28:240-249.

Originalpublikationen im Rahmen der Schweiz. HIV-Kohortenstudie oder anderer Studiengruppen

1. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A, and the Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy [research letter]. *AIDS* 2001;15:1081-2.
2. Quinlivan EB, Wang RX, Stewart PW, Kolmoltri C, Regamey N, Erb P, Vernazza PL; and the Swiss HIV Cohort Study. Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS. *J Med Virol* 2001; 64:157-66.

Übersichtsartikel

1. Flepp M, Schiffer V, Weber R, Hirschel B. Modern Anti-HIV Therapy. *Swiss Med Wkly* 2001;131:207-213.
2. Ruef C, Pittet D, und die Swiss-NOSO CJD Task Force. Prävention der nosokomialen Uebertragung der Creutzfeldt-Jakob Krankheit – neue Herausforderungen und neue Empfehlungen. *Swiss-NOSO* 2001;8: 9-13
3. Ruef C, Sax H. Bio-Terror: Beitrag der Spitalhygiene zu einer wirksamen Antwort. *Swiss-NOSO* 2001;8: 17-20
4. Ruef C, Troillet N. Lüftung im Spital –spitalhygienische Aspekte: I. Operationsabteilungen. *Swiss-NOSO* 2001;8: 6-7
5. Ruef C. Ambulant erworbene Pneumonie: Risikoeinschätzung, empirische und gezielte Therapie. *Ther Umsch* 2001;58: 582-587
6. Troillet N, Francioli P, Pittet D, Ruef C für die Swiss-NOSO Gruppe. (2001) Die Häufigkeit nosokomialer Infektionen als Indikator medizinischer Qualität. *Swiss-NOSO* 2001;7: 1-3
7. The EuroGuidelines Group for HIV Resistance [Miller V, Vandamme AM, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C,

Brun-Vezinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, Pillay D, Schmit JC, Schuurman R, Lange J, Banhegyi D, Biondi G, Broekhuizen A, Bush-Donovan C, Camacho R, Carlier H, Clavel F, Clotet B, Clumeck N, Colebunders R, De Clerq K, De Jaegher JJ, De Schrijver G, De Smet K, Hall W, Harrigan R, Hatzakis A, Hellmann N, Hoetelmans R, Holtzer C, Katlama C, Larder D, Loriaux E, McCreedy B, Mulcahy F, Opravil M, Phillips A, Ruiz N, Shulse E, Sonnerborg A, Soriano V, Steel H, Vella S, Williams A]. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15: 309-320.

Bücher und Buchbeiträge

1. Flepp M, Jost J, Hirschel B, Weber R, Bernasconi E. für die Subkommission Klinik der Eidgenössischen Kommission für AIDS-Fragen. Empfehlungen zur antoretroviralen Therapie 2001, Kap XIV-1.7 1-9 in Jäger H. Aids und HIV-Infektion 33. Erg.Lfg 6/01 Ecomed Verlag, Landsberg.
2. Rued C. (2001) Nosokomiale Infektionen durch Bakterien. In: Krankenhaus- und Praxishygiene, Kramer A, Heeg P, Botzenhart K (eds.), Kapitel 2.4. pp. 92-124, Urban & Fischer Verlag: München, Jena.

Andere Publikationen

1. Reichenberger F, Cathomas G, Weber R, Schoenenberger R, Tamm M. Recurrent fever and pulmonary infiltrates in an HIV-positive patient (Clinico-Pathological Conference). Respiration 2001;68:548-554.
2. Kümmerle U, Günthard HF, Tognola P, Pisoni R, Fischler M. Reiserückkehrer aus Thailand mit Lungeninfiltrat und Kavernen. Schweizerisches Medizin Forum 2001;48:1202-1204.